The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-transitional modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. Human IGFBP-6 cDNA encodes a 240 amino acid (aa) precursor protein with a putative 24 aa signal peptide that is processed to generate the 216 aa mature protein that is O-glycosylated. IGFBP-6 is expressed in ovarian cells, prostatic cells, and fibroblasts. IGFBP-6 is found predominantly in CSF and serum. IGFBP-6 binds preferentially to IGF-II, exhibiting a 2-fold higher affinity for IGF-II than for IGF-I.
Human IGFBP-6 Antibody (164428)
R&D Systems | Catalog # MAB8762
Scientific images may be resized, cropped, or adjusted for brightness or contrast for presentation purposes. These updates are limited to presentation and do not affect the underlying scientific interpretation of the data. Where available, additional source data may be provided upon request.
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Ala25-Gly240
Accession # P24592
Specificity
Clonality
Host
Isotype
Endotoxin Level
Scientific Data Images for Human IGFBP-6 Antibody (164428)
IGFBP‑6 Inhibition of IGF‑II-dependent Cell Proliferation and Neutralization by Human IGFBP‑6 Antibody.
Recombinant Human IGFBP-6 (Catalog # 876-B6) inhibits Recombinant Human IGF-II (Catalog # 292-G2) induced proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IGF-II (14 ng/mL) activity elicited by Recombinant Human IGFBP-6 (0.8 µg/mL) is neutralized (green line) by increasing concen-trations of Mouse Anti-Human IGFBP-6 Monoclonal Antibody (Catalog # MAB8762). The ND50 is typically 5-25 µg/mL.Applications for Human IGFBP-6 Antibody (164428)
Neutralization
Formulation, Preparation, and Storage
Purification
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Calculators
Background: IGFBP-6
References
- Jones, J.I. and D.R. Clemmons (1995) Endocrine Rev. 16:3.
- Kelley, K.M. et al. (1996) Int. J. Biochem. Cell Biol. 28:619.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional IGFBP-6 Products
Product Documents for Human IGFBP-6 Antibody (164428)
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Note: Certificate of Analysis not available for kit components.
Product Specific Notices for Human IGFBP-6 Antibody (164428)
For research use only
Related Research Areas
Citations for Human IGFBP-6 Antibody (164428)
Customer Reviews for Human IGFBP-6 Antibody (164428)
There are currently no reviews for this product. Be the first to review Human IGFBP-6 Antibody (164428) and earn rewards!
Have you used Human IGFBP-6 Antibody (164428)?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 for a review with an image
$10/€7/£6/$10CAN/¥1110 for a review without an image
Submit a review